Compare NMG & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NMG | LCTX |
|---|---|---|
| Founded | 2011 | 1990 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.7M | 251.4M |
| IPO Year | 2015 | 1996 |
| Metric | NMG | LCTX |
|---|---|---|
| Price | $0.94 | $1.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $3.68 | ★ $5.50 |
| AVG Volume (30 Days) | 438.5K | ★ 1.4M |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | N/A | $4.38 |
| Revenue Next Year | N/A | $10.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $0.87 | $0.88 |
| 52 Week High | $3.59 | $2.09 |
| Indicator | NMG | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.55 | 51.56 |
| Support Level | $0.87 | $0.89 |
| Resistance Level | $2.42 | $1.05 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 40.00 | 67.61 |
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The Company currently operates in two segments: the Mining projects (which includes the Matawinie Mine project and the Uatnan Mining Project) and the Battery Material Plant project.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.